|
EQS-Ad-hoc: Formycon AG / Key word(s): Preliminary Results/Forecast Disclosure of inside information according to Article 17 of the Regulation (EU) No 596/2014 Formycon AG increases its outlook for the 2024 fiscal year Planegg-Martinsried, Germany, August 06, 2024 – Formycon AG (ISIN: DE000A1EWVY8 / WKN: A1EWVY) (“Company”) has today decided, based on the preliminary half-year figures, to raise its guidance for the 2024 fiscal year. This affects the key figures adjusted EBITDA[1] and working capital. In its 2023 annual report, the Company had anticipated an At-Equity result of €10.0 million for the 2024 fiscal year. Due to the positive development in the global marketing of the Lucentis®[2] biosimilar FYB201, the Company's At-Equity result in the jointly managed Bioeq AG increased more than expected in the first half of 2024. The earnings contributions totaled €14.8 million as of June 30, 2024, leading to an adjusted EBITDA of -€2.1 million. Consequently, the Company now expects an At-Equity result of approximately €20.0 million for the 2024 fiscal year. Therefore, the Company is raising its guidance for the adjusted EBITDA from the original range of -€15.0 million to -€5.0 million to a new range of -€5.0 million to €5.0 million. The working capital (net current assets including cash and cash equivalents) amounted to €63.0 million as of June 30, 2024, based on the preliminary half-year figures. The European approval process for the Stelara®[3] biosimilar candidate FYB202, which has progressed rapidly and efficiently to date, has led to a positive CHMP opinion earlier than originally anticipated, which means that an earlier EU approval can be expected. The success payment already recognized in revenue is now expected for 2024 and the forecast for working capital has been adjusted from the original range of €10.0 million to €20.0 million to a new range of €35.0 million to €45.0 million. The Company will publish the half-year report 2024 as planned on August 13, 2024. phone +49 (0) 89 – 86 46 67 149
Formycon does not and will not give any assurance that any forward-looking statement will be achieved or prove to be accurate. Actual future business, financial condition, results of operations and prospects may differ materially from those projected or anticipated in the forward-looking statements. Subject to applicable legal requirements, neither Formycon nor any other person intends to update, review, revise or revise any forward-looking statements in this release to reflect actual events or developments, whether as a result of new information becoming available, new developments occurring in the future or otherwise, nor does it undertake any such obligation. [1]Adjusted EBITDA is defined as EBITDA plus the At-Equity result from the jointly managed Bioeq AG. The adjusted Group EBITDA aims to present the total revenue from the FYB201 project, which is partially reported as At-Equity results below EBITDA due to the existing 50% stake in Bioeq AG, as regular operating income. This adjustment allows for a clearer highlight of the direct financial contributions of FYB201 to the Formycon Group's business success and provides a more transparent view of the company's actual operational performance. [2] Lucentis® is a registered trademark of Genentech Inc. [3] Stelara® is a registered trademark of Johnson & Johnson End of Inside Information
06-Aug-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | Formycon AG |
| Fraunhoferstraße 15 | |
| 82152 Planegg-Martinsried | |
| Germany | |
| Phone: | 089 864667 100 |
| Fax: | 089 864667 110 |
| Internet: | www.formycon.com |
| ISIN: | DE000A1EWVY8 |
| WKN: | A1EWVY |
| Indices: | Scale 30 |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Scale), Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1962063 |
| End of Announcement | EQS News Service |
|
|
1962063 06-Aug-2024 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
